000164171 001__ 164171
000164171 005__ 20240229133154.0
000164171 0247_ $$2doi$$a10.1371/journal.pone.0241213
000164171 0247_ $$2pmid$$apmid:33104754
000164171 037__ $$aDKFZ-2020-02300
000164171 041__ $$aeng
000164171 082__ $$a610
000164171 1001_ $$aHassan, Lamiaa$$b0
000164171 245__ $$aThe association between change of soluble tumor necrosis factor receptor R1 (sTNF-R1) measurements and cardiovascular and all-cause mortality-Results from the population-based (Cardiovascular Disease, Living and Ageing in Halle) CARLA study 2002-2016.
000164171 260__ $$aSan Francisco, California, US$$bPLOS$$c2020
000164171 3367_ $$2DRIVER$$aarticle
000164171 3367_ $$2DataCite$$aOutput Types/Journal article
000164171 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611213259_21954
000164171 3367_ $$2BibTeX$$aARTICLE
000164171 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164171 3367_ $$00$$2EndNote$$aJournal Article
000164171 520__ $$aSingle measurements of higher levels of soluble tumor necrosis factor receptor I (sTNF-R1) have been shown to be associated with increased risk of mortality. However, up to date, little is known about the underlying temporal dynamics of sTNF-R1 concentrations and their relation with mortality. We aimed to characterize the effect of changes in sTNFR-1 levels on all-cause and cardiovascular mortality, independent from other established risk factors for mortality, including other inflammatory markers.We used data of the population based cohort study CARLA and included 1408 subjects with sTNF-R1 measured at baseline (2002-2006) and first follow-up (2007-2010). Cox proportional hazard models were used to assess the association of baseline and follow-up sTNF-R1 measurements with all-cause and cardiovascular mortality during ~10 years since the first follow-up after adjusting for relevant confounders.Based on 211 deaths among 1408 subjects, per each doubling of the baseline sTNF-R1, the risk of all-cause mortality was increased by about 30% (Hazard ratio 1.28, 95% Confidence Interval 0.6-2.7), while per each doubling of the follow-up level of sTNF-R1 mortality was 3-fold (3.11, 1.5-6.5) higher in a model including both measurements and adjusting for confounders. The results were mainly related to the cardiovascular mortality (5.9, 2.1-16.8 per each doubling of follow up sTNF-R1 value).Solely the follow-up value, rather than its change from baseline, predicted future mortality. Thus, while sTNF-R1 levels are associated with mortality, particularly cardiovascular, over a long-time period in the general population, if they change, the earlier measurements play no or little role.
000164171 536__ $$0G:(DE-HGF)POF3-323$$a323 - Metabolic Dysfunction as Risk Factor (POF3-323)$$cPOF3-323$$fPOF III$$x0
000164171 588__ $$aDataset connected to CrossRef, PubMed,
000164171 7001_ $$00000-0001-8920-2853$$aMedenwald, Daniel$$b1
000164171 7001_ $$aTiller, Daniel$$b2
000164171 7001_ $$aKluttig, Alexander$$b3
000164171 7001_ $$aLudwig-Kraus, Beatrice$$b4
000164171 7001_ $$00000-0003-4354-9952$$aKraus, Frank Bernhard$$b5
000164171 7001_ $$0P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aGreiser, Karin H$$b6$$udkfz
000164171 7001_ $$aMikolajczyk, Rafael$$b7
000164171 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0241213$$gVol. 15, no. 10, p. e0241213 -$$n10$$pe0241213 -$$tPLOS ONE$$v15$$x1932-6203$$y2020
000164171 909CO $$ooai:inrepo02.dkfz.de:164171$$pVDB
000164171 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000164171 9131_ $$0G:(DE-HGF)POF3-323$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vMetabolic Dysfunction as Risk Factor$$x0
000164171 9141_ $$y2020
000164171 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2018$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-01-05
000164171 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-05
000164171 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-05
000164171 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000164171 980__ $$ajournal
000164171 980__ $$aVDB
000164171 980__ $$aI:(DE-He78)C020-20160331
000164171 980__ $$aUNRESTRICTED